Adcentrx Extends Series A+ Financing to $51M
Summary
Adcentrx Therapeutics, a San Diego, CA- and Shanghai, China-based biotechnology company dedicated to developing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, extended ints Series A+ financing to $51M. The company intends to use the funds to continue advancing its propriety ADC therapeutic pipeline in the clinic. Led by Hui Li, Ph.D., Founder and CEO, Adcentrx is a biotechnology company focused on the protein conjugate therapeutic development for cancer and other life-threatening diseases. The antibody component targets Nectin-4, a cell surface adhesion protein over-expressed in multiple human cancers and associated with poor disease prognosis. ADRX-0706 has a favorable pharmacokinetic and safety profile in preclinical models, and has demonstrated significant efficacy across a variety of tumor indications.